Efficacy and safety of amurubicin for the elderly patients with refractory relapsed small cell lung cancer as third-line chemotherapy
Journal of Cancer Research and Therapeutics, 07/27/2012
Clinical Article
Asai N et al. – Amurubicin (AMR) could be one of the effective tools in the treatment of elderly patients with refractory relapsed small cell lung cancer (SCLC) as third–line chemotherapy, and the recommended dose is 30mg/m2 for three consecutive days.



